Determining whether GLSI is an appropriate purchase depends entirely on an investor's tolerance for extreme clinical-stage biotech risk. While bullish speculators focus on the potential multi-billion-dollar market opportunity if its GP2 breast cancer immunotherapy successfully passes Phase III trials, conservative investors highlight substantial regulatory hurdles, cash burn realities, and binary trial outcome risks.